MX2023000499A - Tratamiento de enfermedades inflamatorias con anticuerpos anti-factor tisular. - Google Patents
Tratamiento de enfermedades inflamatorias con anticuerpos anti-factor tisular.Info
- Publication number
- MX2023000499A MX2023000499A MX2023000499A MX2023000499A MX2023000499A MX 2023000499 A MX2023000499 A MX 2023000499A MX 2023000499 A MX2023000499 A MX 2023000499A MX 2023000499 A MX2023000499 A MX 2023000499A MX 2023000499 A MX2023000499 A MX 2023000499A
- Authority
- MX
- Mexico
- Prior art keywords
- tissue factor
- inflammatory disease
- disease treatment
- factor antibodies
- antibodies
- Prior art date
Links
- 208000027866 inflammatory disease Diseases 0.000 title abstract 3
- 239000000611 antibody drug conjugate Substances 0.000 abstract 4
- 229940049595 antibody-drug conjugate Drugs 0.000 abstract 4
- 101000635804 Homo sapiens Tissue factor Proteins 0.000 abstract 1
- 108010000499 Thromboplastin Proteins 0.000 abstract 1
- 102000002262 Thromboplastin Human genes 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/68031—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being an auristatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6843—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/36—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against blood coagulation factors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/77—Internalization into the cell
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Virology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Hematology (AREA)
- Biophysics (AREA)
- Rheumatology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Cardiology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Zoology (AREA)
- Physical Education & Sports Medicine (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Pulmonology (AREA)
- Heart & Thoracic Surgery (AREA)
- Endocrinology (AREA)
- Pain & Pain Management (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
Se proporcionan en la presente anticuerpos que se unen específicamente al factor tisular humano (TF), conjugados de anticuerpo-fármaco anti-TF (ADC) y composiciones que comprenden los anticuerpos o ADC para el tratamiento de enfermedades inflamatorias. También se proporcionan en la presente métodos para tratar sujetos que tienen enfermedades inflamatorias mediante la administración de anticuerpos anti-TF o ADC.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US202063050629P | 2020-07-10 | 2020-07-10 | |
PCT/US2021/041192 WO2022011324A1 (en) | 2020-07-10 | 2021-07-10 | Inflammatory disease treatment using anti-tissue factor antibodies |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2023000499A true MX2023000499A (es) | 2023-04-20 |
Family
ID=79552117
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2023000499A MX2023000499A (es) | 2020-07-10 | 2021-07-10 | Tratamiento de enfermedades inflamatorias con anticuerpos anti-factor tisular. |
Country Status (13)
Country | Link |
---|---|
US (1) | US20240166765A1 (es) |
EP (1) | EP4178608A1 (es) |
JP (1) | JP2023534191A (es) |
KR (1) | KR20230037042A (es) |
CN (1) | CN116322713A (es) |
AU (1) | AU2021304359A1 (es) |
BR (1) | BR112023000455A2 (es) |
CA (1) | CA3184987A1 (es) |
CL (1) | CL2023000099A1 (es) |
IL (1) | IL299632A (es) |
MX (1) | MX2023000499A (es) |
TW (1) | TW202216198A (es) |
WO (1) | WO2022011324A1 (es) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2023137399A2 (en) * | 2022-01-12 | 2023-07-20 | Iconic Therapeutics Llc | Inflammatory disease treatment using anti-tissue factor antibodies |
WO2023160651A1 (zh) * | 2022-02-24 | 2023-08-31 | 苏州信诺维医药科技股份有限公司 | 一种抗体及其药物偶联物和用途 |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2003527861A (ja) * | 2000-03-16 | 2003-09-24 | ジェネンテック・インコーポレーテッド | 増強した抗血液凝固能を持つ抗組織因子抗体 |
US20060104944A1 (en) * | 2004-11-18 | 2006-05-18 | Mousa Shaker A | Activators and inhibitors of protease activated receptor2 (PAR2) and methods of use |
AU2006311661B2 (en) * | 2005-11-07 | 2011-05-26 | The Scripps Research Institute | Compositions and methods for controlling tissue factor signaling specificity |
UA109633C2 (uk) * | 2008-12-09 | 2015-09-25 | Антитіло людини проти тканинного фактора | |
US8722044B2 (en) * | 2011-03-15 | 2014-05-13 | Janssen Biotech, Inc. | Human tissue factor antibody and uses thereof |
BR112020013679A2 (pt) * | 2018-01-04 | 2020-12-01 | Iconic Therapeutics, Inc. | anticorpos de fator antitecidual, conjugados anticorpo-fármaco e métodos relacionados |
-
2021
- 2021-07-10 CA CA3184987A patent/CA3184987A1/en active Pending
- 2021-07-10 BR BR112023000455A patent/BR112023000455A2/pt unknown
- 2021-07-10 AU AU2021304359A patent/AU2021304359A1/en active Pending
- 2021-07-10 IL IL299632A patent/IL299632A/en unknown
- 2021-07-10 WO PCT/US2021/041192 patent/WO2022011324A1/en unknown
- 2021-07-10 JP JP2023501429A patent/JP2023534191A/ja active Pending
- 2021-07-10 EP EP21836909.8A patent/EP4178608A1/en active Pending
- 2021-07-10 KR KR1020237004394A patent/KR20230037042A/ko unknown
- 2021-07-10 CN CN202180054909.3A patent/CN116322713A/zh active Pending
- 2021-07-10 MX MX2023000499A patent/MX2023000499A/es unknown
- 2021-07-10 US US18/015,532 patent/US20240166765A1/en active Pending
- 2021-07-12 TW TW110125563A patent/TW202216198A/zh unknown
-
2023
- 2023-01-10 CL CL2023000099A patent/CL2023000099A1/es unknown
Also Published As
Publication number | Publication date |
---|---|
AU2021304359A1 (en) | 2023-03-02 |
CL2023000099A1 (es) | 2023-08-11 |
KR20230037042A (ko) | 2023-03-15 |
CA3184987A1 (en) | 2022-01-13 |
JP2023534191A (ja) | 2023-08-08 |
BR112023000455A2 (pt) | 2023-03-28 |
EP4178608A1 (en) | 2023-05-17 |
US20240166765A1 (en) | 2024-05-23 |
TW202216198A (zh) | 2022-05-01 |
CN116322713A (zh) | 2023-06-23 |
IL299632A (en) | 2023-03-01 |
WO2022011324A1 (en) | 2022-01-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CL2023000099A1 (es) | Tratamiento de enfermedades inflamatorias con anticuerpos anti-factor tisular | |
PH12020551037A1 (en) | Anti-tissue factor antibodies, antibody-drug conjugates, and related methods | |
MX2021015974A (es) | Conjugados de anticuerpos y farmacos anti-factor tisular y metodos relacionados. | |
CR10244A (es) | Terapia tumoral con un anticuerpo contra el factor de crecimiento endotelial vascular y un anticuerpo contra el receptor del factor de crecimiento epitelial tipo 2 humano | |
DK1140170T3 (da) | Antistoffragmenter til topisk behandling af öjensygdomme | |
BRPI0317376B8 (pt) | proteína de fusão de anticorpo-il2 designada como hu14.18-il2, usos da mesma, vetor e composição farmacêutica | |
MY145042A (en) | Humanized monoclonal antibodies to hepatocyte growth factor | |
BRPI0514199A (pt) | método de efetuar profilaxia ou tratar uma doença, composição farmacêutica, anticorpo monoclonal, célula de hibridoma, e, método de triar um agente, de humanizar anticorpo monoclonal 8a5 ou anticorpo monoclonal 6h7 e de produzir uma forma quimérica de anticorpo monoclonal 8a5 ou anticorpo monoclonal 6h7 | |
ATE557042T1 (de) | Anti-myostatin-antikörper | |
UA109633C2 (uk) | Антитіло людини проти тканинного фактора | |
EA200870254A1 (ru) | Способ лечения воспалительных заболеваний | |
MX2021010453A (es) | Conjugados anticuerpo-farmaco que comprenden anticuerpos contra dlk1 humana y uso de estos. | |
TN2009000380A1 (en) | Novel human anti-r7v antibodies and uses thereof | |
EA202092518A1 (ru) | Композиции и способы лечения рака | |
MX2020008208A (es) | Agentes de unión a fibroblastos y uso de estos. | |
WO2021090062A8 (en) | Anti-mesothelin eribulin antibody-drug conjugates and methods of use | |
MX2022001841A (es) | Anticuerpos contra ilt2 y uso de los mismos. | |
EA202092136A1 (ru) | Способы лечения рака с помощью комбинации антитела к pd-1 и конъюгата антитела к тканевому фактору и лекарственного средства | |
PH12020500417A1 (en) | Anti-efgr antibody drug conjugates (adc) and uses thereof | |
CO2022011195A2 (es) | Composiciones y métodos para aumentar o mejorar la transducción de vectores de terapia génica y para eliminar o reducir inmunoglobulinas | |
BR112022019853A2 (pt) | Imunoconjugado que se liga especificamente a eno-1, composição para diagnóstico ou imagem de células ou de um tecido que expressa eno-1, composição farmacêutica para uso no tratamento de uma doença inflamatória, método para tratar uma doença inflamatória, e uso do imunoconjugado | |
WO2021056025A3 (en) | Anti-epha10 antibodies and methods of use thereof | |
WO2023137399A3 (en) | Inflammatory disease treatment using anti-tissue factor antibodies | |
MX2022010945A (es) | Usos terapeuticos de compuestos macrociclicos. | |
WO2019089594A8 (en) | Combination treatment with antibody-drug conjugates and cytarabine |